Drug intelligence / Profile preview

NCE-DPOCL

Development stage: Preclinical
Lead developer: Centaur Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

NCE-DPOCL is a small molecule new chemical entity (NCE) being developed by Centaur Pharmaceuticals for the treatment of diabetic foot ulcers (DFU). The molecule is identified in the company's pipeline as an in-licensed asset within their clinical research program. As of the current reporting, specific details regarding its biological target, mechanism of action, and clinical development phase have not been publicly disclosed by the sponsor. The program represents part of Centaur's specialized portfolio for chronic wound management in diabetic patients.

Beyond the preview

Go deeper on NCE-DPOCL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NCE-DPOCL.

Explore the full profile